Previous Article | Next Article 
Molecular and Cellular Biology, September 2000, p. 6518-6536, Vol. 20, No. 17
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
The SH3 Domain Directs Acto-Myosin-Dependent
Targeting of v-Src to Focal Adhesions via Phosphatidylinositol
3-Kinase
Valerie J.
Fincham,
Valerie
G.
Brunton, and
Margaret C.
Frame*
The Beatson Institute for Cancer research,
CRC Beatson Laboratories, Bearsden, Glasgow G61 1BD, United Kingdom
Received 6 April 2000/Accepted 17 May 2000
 |
ABSTRACT |
The v-Src oncoprotein is translocated to integrin-linked focal
adhesions, where its tyrosine kinase activity induces adhesion disruption and cell transformation. We previously demonstrated that the
intracellular targeting of Src is dependent on the actin cytoskeleton,
under the control of the Rho family of small G proteins. However, the
assembly of v-Src into focal adhesions does not require its catalytic
activity or myristylation-dependent membrane association. Here, we
report that the SH3 domain is essential for the assembly of focal
adhesions containing the oncoprotein by mediating a switch from a
microtubule-dependent, perinuclear localization to actin-associated focal adhesions; furthermore, v-Src translocation to focal adhesions requires myosin activity, at least under normal conditions when the
actin cytoskeleton is being dynamically regulated. Although the SH3
domain of v-Src is also necessary for its association with focal
adhesion kinase (FAK), which is often considered a likely candidate
mediator of focal adhesion targeting via its carboxy-terminal targeting
sequence, we show here that binding to FAK is not essential for the
targeting of v-Src to focal adhesions. The p85 regulatory subunit of
phosphatidylinositol (PI) 3-kinase also associates with v-Src in an
SH3-dependent manner, but in this case inhibition of PI 3-kinase
activity suppressed assembly of focal adhesions containing the
oncoprotein. Thus, the Src SH3 domain, which binds PI 3-kinase and
which is necessary for activation of Akt downstream, is required for
the actin-dependent targeting of v-Src to focal adhesions.
 |
INTRODUCTION |
The dynamic regulation of the
eukaryotic cell adhesion network and cytoskeleton controls cell shape,
adhesive strength, and dependent physiological processes such as cell
motility. In addition, adhesive interactions themselves can contribute
to cytoskeletal organization and, reciprocally, the cellular
cytoskeleton can influence the assembly and function of cell
interactions, including those mediated by both integrins and cadherins
(48). Thus, the interplay between the assembly-disassembly
cycles of cellular adhesions and the cytoskeleton is both complex and
crucial to the proper functioning of the cell. Although a great deal of
information about the dynamic regulation of the adhesion and
cytoskeletal network has been gathered over the past decade
(48), including the important role played by the Rho family
of GTP-binding proteins (27), we still lack an understanding
of the link between the biochemical regulators and the biophysical
changes that lead to altered cell structure.
Focal adhesions are specialized structures where cells contact the
surrounding extracellular matrix (ECM) (6, 7, 33). They
consist of clustered integrin heterodimers, structural or cytoskeleton-associated proteins that link the ECM, through the integrins, to the actin cytoskeleton, and proteins involved in intracellular signal transduction (reviewed in reference
3). While it is well accepted that focal adhesion
structures are constantly being assembled, altered, and disassembled as
cells move or respond to their extracellular environment, the mechanics
of integrin clustering and focal adhesion assembly and how these events
are tightly controlled by biochemical signals within the cell remain to
be established. One particularly complex relationship is that between
focal adhesion dynamics and tyrosine phosphorylation. On one hand,
focal adhesions can clearly form in the absence of detectable tyrosine
phosphorylation of their components (19, 23), while on the
other, agents that stimulate tyrosine phosphorylation often promote
focal adhesion formation (reviewed in reference 48).
An explanation for these apparently paradoxical findings is that
tyrosine phosphorylation at focal adhesions is required for the
assembly of signaling complexes, mediated in part by SH2 domain-phosphotyrosine interactions, but that assembly of focal adhesion components into adhesive structures does not require tyrosine
phosphorylation (reviewed in reference 48).
Furthermore, for cells transformed by the v-Src tyrosine kinase there
is abundant evidence that tyrosine phosphorylation of both structural
and signaling proteins at focal adhesions is linked to adhesion
disassembly and to disruption of the associated actin cytoskeleton;
most likely, these effects are mediated by direct tyrosine
phosphorylation of adhesion components (8, 19, 20, 24, 28,
42) rather than via altered gene expression (4, 21).
These tyrosine kinase-induced changes result in the loss of normal
control of cell adhesion and actin organization evident during
oncogenic transformation and lead to deregulation of processes that are dependent on these cellular structures.
In order to understand further the regulation of focal adhesion
assembly, we have studied the intracellular targeting of a v-Src
protein that is temperature dependent (ts) for both focal adhesion targeting and transformation. This molecular tool allows the
conditional assembly of focal adhesions in which v-Src is present and
has enabled us to address the molecular determinants and features of
the assembly process. Specifically, at the nonpermissive temperature,
the ts LA29 v-Src protein locates around the perinuclear region of the cell (17, 18). Upon activation by a switch to the permissive temperature, v-Src colocalizes with actin stress fibers
and is assembled into focal adhesions by a process that is dependent on
the activity of Rho family proteins and the integrity of the actin
cytoskeleton (17, 18). Other focal adhesion components, including focal adhesion kinase (FAK) and paxillin, colocalize with
v-Src as discrete protein complexes in the cell interior at early times
after v-Src activation and in focal adhesions at the cell periphery at
later times, indicating that v-Src is coassembled with these proteins
into peripheral adhesions (17).
To study the structural determinants of v-Src translocation, we used
mutant derivatives of ts LA29 v-Src that were constitutively kinase inactive or myristylation defective to demonstrate that neither
catalytic activity nor N-terminal myristylation is required for the
assembly of v-Src into focal adhesions (17). However, both
tyrosine kinase activity and myristylation-mediated membrane association are required for v-Src-induced focal adhesion turnover during transformation and cell motility (17). In this study, we demonstrate that inactive v-Src is apparently constrained in the
perinuclear region of the cell by the microtubule network. Upon
activation, this constraint is removed and v-Src associates with
polymerized actin and is assembled into focal adhesions at the cell
periphery, events that normally require the integrity of the SH3 domain
of v-Src, its association with phosphatidylinositol (PI) 3-kinase, and
myosin-induced bundling of actin filaments.
 |
MATERIALS AND METHODS |
Generation of CE cells expressing v-Src mutants and FAK.
Primary chicken embryo (CE) cells were routinely grown in Dulbecco's
modified Eagle's medium supplemented with 5% newborn calf serum, 1%
chick serum, and 10% tryptose phosphate. The generation of
v-Src-expressing CE cells was similar to that described previously (17). Briefly, cultures were transfected with
replication-competent avian retroviral RAV-src or
RCAS-fak constructs (5 µg per 25-cm2 flask) by
the DOTAP method (Roche) and subcultured at the permissive temperature
of 35°C until the cultures were uniformly infected and were
expressing Src protein (judged by protein immunoblotting). The
generation of retrovirus encoding ts LA29 v-Src has been
described (51). Retrovirus encoding the kinase-defective
(KD) variant of ts LA29 v-Src was generated by converting
the ATP binding site at position 295 from Lys to Arg using PCR
mutagenesis as described previously (17). A mutation that
has previously been shown to inhibit SH3 domain-binding activity (Trp
to Ala at position 118 of Src) (15) was introduced to
ts LA29 v-Src using the mutant sense oligonucleotide 5'-GAA
GGT GAC GCG TGG CTG GCT CA-3' to produce ts LA29
v-Src-W118A. A Tyr-to-Phe mutation at position 397 of avian FAK was
generated using the mutant sense oligonucleotide 5'-CAG AAA CAG ATG ACT
TTG CAG AGA TAA TAG ATG-3'. To detect exogenous FAK, a myc
tag sequence was introduced at the BclI site at position 3186 of the avian fak sequence using the double-stranded
oligonucleotide encoding the c-Myc 9E10 epitope with
BclI-compatible termini. RCAS-Pro2 FAK was myc
tagged as described above. For experiments that required coexpression
of both v-Src and myc-tagged FAK, v-Src was cloned into the
replication-defective, neomycin-selectable avian retrovirus SFCV-LE
(22). Cell cultures infected with retroviruses encoding
ts v-Src mutants and/or myc-tagged FAK were grown
either at the restrictive (41°C) or permissive (35°C) temperature
and were buffered with 5% CO2.
Generation of FAK
/
cells expressing v-Src.
FAK
/
cells that were also null for p53 (as described in
reference 32) were cultured in Dulbecco modified
Eagle medium supplemented with 1% nonessential amino acids, 10% fetal
calf serum, and 10 µM 2-mercaptoethanol at 37°C. They were
transiently transfected with the murine retrovirus FpGV-1
(11) containing wild-type PrA v-Src using Superfect
(Qiagen), maintained at 37°C for 24 h, and then fixed and
stained for v-Src as described above for CE cells.
Protein immunoprecipitation and immunoblotting.
For protein
analyses, dishes of cells were washed with cold phosphate-buffered
saline (PBS) and drained. For immunoprecipitation, monolayers were
lysed in radioimmunoprecipitation assay (RIPA buffer) (50 mM Tris [pH
7.4], 150 mM NaCl, 5 mM EGTA, 0.1% sodium dodecyl sulfate [SDS],
1% NP40, 1% deoxycholate) with inhibitors (10 mM pyrophosphate, 0.5 mM sodium fluoride, 1 mM phenylmethylsulfonyl fluoride [PMSF], 10 µg of aprotinin [Sigma]/ml, 100 µM sodium vanadate, 10 µg of
leupeptin [Sigma]/ml, 10 µg of benzamidine [Sigma]/ml), clarified
by a high-speed spin at 4°C, and precleared with normal
immunoglobulin G (IgG) and protein A-Sepharose (Sigma). Cell lysate
(750 µg; measured by the Micro BCA protein assay kit [Pierce]) was
immunoprecipitated with 2 µg of anti-Src monoclonal antibody (MAb)
EC10 (Upstate Biotechnology) or 5 µl of anti-FAK carboxy-terminal
peptide serum. Immune complexes were collected on either protein
A-Sepharose, anti-mouse IgG-coated protein A-Sepharose, or anti-mouse
IgG-conjugated agarose (Sigma); precipitated proteins were washed four
times with RIPA buffer and once with 0.6 M lithium chloride, eluted
using buffer containing a high level of SDS at high temperature, and
separated by SDS-7.5% polyacrylamide gel electrophoresis (PAGE).
v-Src and FAK or their associated proteins were detected by
transferring immunoprecipitated proteins to nitrocellulose, blocking
with 3% bovine serum albumin (Sigma) or 5% low fat milk in PBS-0.2%
Tween 20 (Sigma), and probing with EC10 (Upstate Biotechnology) at
1:1,000, anti-FAK (Transduction Laboratories) at 1:500, anti-Myc horseradish peroxidase (HRP) conjugate (Invitrogen) at 1:2,000, anti-HSP-90 (Upstate Biotechnology) at 1:400, anti-p110AFAP
(Transduction Laboratories) at 1:250, or anti-p85 (Upstate
Biotechnology) at 1:200. Detection was by incubation with
HRP-conjugated secondary antibody, and visualization was by enhanced
chemiluminescence (Amersham). To monitor protein expression in
whole-cell lysates, 5 or 20 µg of total protein was separated by
SDS-PAGE and immunoblotted using antibodies as described above,
anti-Akt or anti-Akt phosphorylated at Ser-473
(anti-phospho-Akt-Ser-473) (New England Biolabs), both at 1:1,000, or
anti-phospho-Src-Tyr-416 (Biosource Inc.) at 1:1,000.
Immunofluorescence.
Subconfluent cells were grown on glass
coverslips at the nonpermissive temperature (41°C) and shifted to the
permissive temperature (35°C) in some cases. Inhibitors were added to
the cultures 1 h prior to the temperature shift (unless otherwise
stated) at the following concentrations: BDM (Sigma), 10 mM; nocodazole
(Sigma), 0.5 µg/ml; LY294002 (Calbiochem), 20 µM; ML-7
(Calbiochem), 25 µM. Cells were fixed at 4°C for 15 min with 3.7%
formaldehyde, permeabilized with 0.5% Triton X-100, and incubated with
primary antibodies at the following concentrations: 1:500 for anti-Src MAb EC10, 1:500 for anti-Src rabbit polyclonal antibody MW2
(51), 1:500 for anti-
-tubulin (Sigma), 1:200 for anti-Myc
9E10 (Roche), 1:200 for anti-myosin light chain (MLC) (Sigma), 1:200
for antipaxillin (Transduction Laboratories, and 1:500 for anti-FAK BC3
(Upstate Biotechnology). Antibody detection was by reaction with
fluorescein isothiocyanate (FITC)- or Texas red-conjugated secondary
antibodies (Jackson Laboratories) at 1:200 for 45 min at room
temperature. As a control, cells were incubated with secondary antibody
alone (not shown). To visualize actin stress fibers, cells were stained with FITC- or tetramethyl rhodamine isocyanate-conjugated phalloidin at
1 µg/ml (Sigma). Stained cells were visualized by optical sectioning with a confocal microscope (model MRC 600; Bio-Rad), and images were
printed on a dye sublimation printer (Kodak).
Cytoskeletal protein preparations.
F-actin fractionation was
carried out with minor modifications to a procedure described
previously (44). Briefly, cell monolayers were washed with
cold PBS, and cytoskeletons were extracted in CSK buffer (0.5% Triton
X-100, 20 mM HEPES [pH 7.4], 50 mM NaCl, 1 mM EGTA, 1 mM PMSF, 10 µg of leupeptin/ml, 100 µM sodium vanadate, 5 µg of
aprotinin/ml). The insoluble material was pelleted at 12,000 × g for 5 min at 4°C and washed twice with cold CSK buffer. The
pellet was dissolved in 0.6 M KI-100 mM PIPES
(piperazine-N,N'-bis(
-ethanesulfonic acid) (pH
6.5)-100 mM KCl-10 µg of leupeptin/ml-1 mM PMSF-100 µM sodium
vanadate at 4°C for 30 min. Insoluble material was pelleted at
40,000 × g for 20 min at 4°C, and the supernatant
was extensively dialyzed against 10 mM PIPES (pH 6.8)-0.5 mM EGTA-2
mM MgCl2-1 mM PMSF-5 mM benzamidine-100 µM sodium
vanadate. The resulting granular precipitate, enriched in F-actin, was
collected by centrifugation at 12,000 × g for 5 min at
4°C. A further round of solubilization and dialysis was performed,
and the precipitate was dissolved in SDS sample buffer. Preparations
were normalized with respect to actin concentration by titration on
SDS-PAGE minigels and immunoblotted using anti-Src EC10 as described
above and antiactin (Sigma) at 1:500.
 |
RESULTS |
The SH3 domain of v-Src is required for actin association and
assembly of v-Src into focal adhesions.
To determine the
requirements of v-Src's intracellular targeting to focal adhesions, we
previously mutated the catalytic site and the site of myristylation to
show that neither kinase activity nor amino-terminal myristylation was
required. Here, we have investigated the role of the SH3 domain by
generating a mutant v-Src protein, ts LA29 v-Src-W118A, that
inhibits SH3-binding interactions (15). This rendered the
v-Src protein incapable of translocation to focal adhesions upon a
shift to the permissive temperature (Fig. 1A, right). Compared to ts
LA29 v-Src or its kinase-defective variant (Fig. 1A, left and
center, respectively), the SH3 mutant v-Src protein remained
cytoplasmic, even after prolonged times at the permissive temperature
(Fig. 1A, right). Although v-Src was unable to assemble into focal
adhesions in the absence of SH3 function, paxillin was still evident in
residual focal adhesions of cells expressing the ts v-Src
SH3 mutant protein (Fig. 1A, lower right). However, we noted that
long-term expression of ts LA29 v-Src-W118A at the
permissive temperature had a detrimental effect on cell growth and
viability (not shown), implying that the presence of active Src kinase
in the cytoplasm or the inability to assemble new focal adhesions in
the presence of the v-Src SH3 mutant was toxic.


View larger version (124K):
[in this window]
[in a new window]
|
FIG. 1.
The SH3 domain of ts LA29 v-Src is required
for translocation and actin association. (A) CE cells expressing
ts LA29 v-Src, its KD variant ts LA29 v-Src-KD,
or ts LA29 v-Src which has a point mutation in the SH3
domain (W118A) were maintained at 41°C or were shifted to 35°C for
2, 7, or 24 h prior to staining with anti-Src (and antipaxillin
for cells after 24 h at 35°C) and a secondary antibody coupled
to Texas red or FITC. Bars, 25 µm. (B) CE cells expressing ts
LA29 v-Src or its kinase-defective variant, ts LA29
v-Src-KD, or the SH3 domain mutant, ts LA29 v-Src-W118A were
maintained at 41°C or were shifted to 35°C for 30 or 60 min.
Cytoskeletons were extracted and subjected to two rounds of partial
depolymerization and repolymerization as described in Materials and
Methods. After the final polymerization, preparations were solubilized
and proteins were separated by SDS-10% PAGE and immunoblotted using
anti-Src or antiactin as the probe. As a control (B, top left), a
whole-cell lysate of ts v-Src-expressing cells grown at
35°C was immunoblotted with anti-Src. (C) Whole-cell lysates of
ts LA29 v-Src, ts LA29 v-Src-KD-, or ts
LA29 v-Src-W118A-expressing cells were immunoblotted using
anti-Src-phospho-Tyr-416 (upper) or anti-Src (lower) as the probe. The
positions of v-Src are indicated. CEF, CE fibroblasts.
|
|
Our previous work demonstrated colocalization of activated
ts v-Src with the actin cytoskeleton (18).
Therefore, we tested whether we could demonstrate a biochemical
association between v-Src and cellular polymerized actin and whether
this was influenced by SH3 domain integrity. Cytoskeletons were
extracted from CE cells expressing ts LA29 v-Src at the
restrictive temperature and after the shift to the permissive
temperature and subjected to 2 cycles of partial depolymerization and
polymerization by treatment with KI and dialysis, respectively (as
described previously [44] and in Materials and
Methods). At the restrictive temperature, ts LA29 v-Src was
not visibly associated with polymerized actin (Fig. 1B, upper left).
However, after the shift to the permissive temperature, association was
readily detected by 30 min and continued to increase at 60 min (Fig.
1B, upper left). Consistent with the ability of a KD mutant of ts
LA29 v-Src to translocate to focal adhesions (17), this
mutant v-Src protein also associated with polymerized actin after the
switch to the permissive temperature (Fig. 1B, upper middle). In
contrast, although there was some detectable association of the
v-Src-W118A SH3 mutant with polymerized actin at the restrictive
temperature, this was not stimulated by the switch to the permissive
temperature (Fig. 1B, upper right). The relative amount of cellular
actin under each of these conditions is shown (Fig. 1B, lower). Thus,
activation of ts LA29 v-Src induces an SH3-dependent
increase in association with polymerized actin and translocation to
focal adhesions at the termini of actin stress fibers. Since there was
a small amount of the v-Src-W118A SH3 mutant apparently binding to
actin, even at the restrictive temperature (Fig. 1B), it is formally
possible that functional SH3 interactions might normally suppress the
association of a small proportion of inactive v-Src with actin;
however, while the v-Src proteins that translocate to focal adhesions
showed a substantial increase in association with cellular actin after
activation, the SH3 mutant did not.
To determine expression levels and states of activity of the
ts v-Src mutants, we probed lysates with anti-Src (Fig. 1C,
lower) or with an antiserum that we have previously used to monitor the activation-specific Src Tyr-416 residue in its phosphorylated form
(43) (Fig. 1C, upper). These immunoblots confirmed that exogenous v-Src was expressed (no c-Src was detected at this exposure, as can be judged by the lack of signal in CE fibroblast lysate [Fig.
1C, lower]) and that both ts LA29 v-Src and the SH3 mutant, ts LA29 v-Src-W118A were enzymatically active after the
shift to the permissive temperature (Fig. 1C, upper).
Integrin-induced assembly of new focal adhesions containing v-Src
is SH3 dependent.
Since our work on the targeting of v-Src to
focal adhesions has been carried out with adherent cells, we sought to
determine whether v-Src was incorporated into newly assembling focal
adhesions after integrin engagement. Thus, cells expressing
ts v-Src were plated onto fibronectin and onto
poly-L-lysine for comparison. We found that v-Src did not
translocate to the cell periphery when cells were plated on
poly-L-lysine (Fig. 2A,
upper), indicating a requirement for integrin
engagement induced after attachment to fibronectin (Fig. 2A, lower).
The finding that the peripheral targeting of v-Src was integrin
dependent was surprising, since activated v-Src is often regarded as a
surrogate integrin signal that can function independently of cellular
integrin function. That control of the peripheral targeting of v-Src
was integrin dependent implies that the "inside-out" signaling
required for focal adhesion assembly after integrin engagement is also
necessary for the assembly of focal adhesions containing the
oncoprotein in adherent cells. This further suggests that studying the
requirements for the assembly of focal adhesions that are tracked by
the presence of ts v-Src after the switch to the permissive
temperature is relevant also to integrin-induced focal adhesion
assembly. In this regard, we found that cells expressing the v-Src SH3
mutant, ts LA29 v-Src-W118A, were impaired at spreading on
fibronectin, with apparently fewer focal adhesions formed (Fig. 2B,
right). To monitor spreading on fibronectin with another focal adhesion protein, we double-stained cells expressing ts v-Src or the
SH3 mutant with both anti-Src and antipaxillin. This showed that
ts v-Src colocalized with paxillin during the formation of
multiple focal adhesions as cells spread on fibronectin at the
permissive temperature (Fig. 2C, upper). In contrast, the assembly of
focal adhesions containing paxillin was impaired by the SH3 mutant of v-Src (Fig. 2C, lower); however, in cells expressing low levels of the
SH3 mutant v-Src protein, some paxillin staining in small structures at
the cell periphery was evident (Fig. 2C, lower right). Thus,
overexpression of the SH3 mutant v-Src protein impairs focal adhesion
assembly after cells have attached to fibronectin, indicating a need
for SH3 adapter function for integrin-induced focal adhesion assembly,
as well as for assembly of focal adhesions containing v-Src in adherent
cells.


View larger version (148K):
[in this window]
[in a new window]
|
FIG. 2.
The peripheral targeting of v-Src is integrin dependent.
(A) CE cells expressing ts LA29 v-Src that had been grown at
41°C were trypsinized, held in suspension, and plated onto
poly-L-lysine- or fibronectin-coated dishes for 40 min at
either 41 or 35°C. Fixed cells were stained with anti-Src (and a
secondary antibody coupled to FITC). (B) CE cells expressing the SH3
domain mutant, ts LA29 v-Src-W118A, were plated onto
fibronectin for 40 min at either 41 or 35°C. (C) CE cells expressing
ts LA29 v-Src or the SH3 domain mutant, ts LA29
v-Src-W118A, were plated onto fibronectin for 40 min at 35°C. Fixed
cells were stained with anti-Src and antipaxillin (and secondary
antibodies coupled to Texas red or FITC). Broken arrows indicate small
structures at all periphery; some paxillin staining is visible in the
lower right panel. Bars, 25 µm.
|
|
Inactive v-Src is constrained in the perinuclear region by the
microtubule network and switches to actin after activation.
In our
previous studies with serum-deprived Swiss 3T3 and CE cells, we found
that ts v-Src rapidly translocated from the perinuclear region to focal adhesions at the cell periphery in association with
actin stress fibers. To further investigate the cytoskeletal associations during the peripheral targeting of v-Src, we costained CE
cells at the nonpermissive temperature (41°C) with anti-
-tubulin and anti-Src. We found that, in their inactive state, v-Src and
-tubulin displayed similar levels of perinuclear staining (Fig. 3A). Furthermore, upon treatment of cells
at the nonpermissive temperature with 0.5 µg of
nocodazole/ml, v-Src was no longer perinuclear (Fig. 3B), implying that
the tight retention of inactive v-Src in the perinuclear region was
dependent on the integrity of the microtubule network.


View larger version (128K):
[in this window]
[in a new window]
|
FIG. 3.
Inactive v-Src colocalizes with regions of dense tubulin
staining and switches to actin after activation. Confocal images are of
CE cells expressing ts LA29 v-Src stained with anti-Src (and
a secondary antibody coupled to Texas red) and anti- -tubulin (and a
secondary antibody coupled to FITC). v-Src was maintained in the
inactive state at 41°C, and cells were either untreated (A) or
treated with 0.5 µg of nocodazole/ml (B). Arrows (A), regions of
colocalization of v-Src and tubulin. (C) Cells were stained with
anti-Src (visualized as red) and anti- -tubulin (visualized as green)
after the switch to the permissive temperature (35°C) for 2 h.
In the merged image, v-Src-staining focal adhesions at the cell
periphery are indicated by arrows. (D) v-Src-containing complexes at
the ends of MLC-staining filaments are shown in CE cells expressing
ts LA29 v-Src that were shifted to 35°C for 1 h and
double stained with both anti-Src (followed by a secondary antibody
coupled to FITC) and anti-MLC (followed by a secondary antibody coupled
to Texas red). (E) CE cells expressing ts LA29 v-Src were
shifted to 35°C for 1 h and double stained with both anti-Src
(followed by a secondary antibody coupled to FITC) and
phalloidin-tetramethyl rhodamine isocyanate. Arrows, v-Src-containing
complexes colocalizing with the ends of actin filaments. Bars, 25 µm.
|
|
As we showed previously (17, 18), some of the expressed
v-Src was recruited to focal adhesions at the cell periphery upon activation by the shift to the permissive temperature (35°C) (Fig. 3C). Furthermore, these peripheral v-Src-containing focal adhesions were associated with actin stress fibers (17, 18) (Fig. 3E). Here we showed by double staining with anti-Src and anti-
-tubulin after 2 h at the permissive temperature that most of the adhesion structures containing Src no longer colocalized with dense regions of
tubulin staining in the perinuclear region (Fig. 3C). Thus, upon the
switch to the permissive temperature, v-Src is released from its
microtubule-dependent localization in the perinuclear region of the
cell, becomes associated with actin, and is assembled into focal
adhesions at the ends of actin stress fibers. However, our experiments
have not distinguished whether the switch to actin occurs in the
perinuclear region or close to sites of formation of peripheral focal
adhesions. Nonetheless, the formation of v-Src-containing focal
adhesions is apparently independent of microtubules once assembly has
been initiated by a shift to the permissive temperature (18).
Myosin ATPase activity is required for translocation of
kinase-active v-Src, but not kinase-defective v-Src, to focal
adhesions.
Since we have established that translocation of
ts LA29 v-Src to the cell periphery requires release from
the perinuclear region and association with actin mediated by the Src
SH3 domain, we sought to refine our understanding of the determinants
of actin organization that contribute to the assembly of focal
adhesions containing v-Src. Our previous work demonstrated the
involvement of the small G protein RhoA, mediated by its effects on
actin organization (18). Here we have also addressed the
role of myosin during conditions under which the actin cytoskeleton was
being dynamically regulated or was stabilized by the dominant-negative action of overexpressed KD v-Src. First, we stained CE cells with an
antibody to MLC and found that it localized along actin stress fibers
(Fig. 3D). However, in contrast to the phalloidin-stained actin stress
fibers that overlapped with v-Src at the stress fiber termini
(visualized as yellow in the merged image in Fig. 3E), MLC was mostly
excluded from the v-Src-containing focal adhesions (as judged by the
predominantly green staining of v-Src in the merged image in Fig. 3D).
Since the ATPase activity of myosin is regulated by phosphorylation of
MLC by MLC kinase (MLCK) (1, 12), we tested whether the MLC
associated with stress fibers was involved in v-Src translocation. For
this, we used butanedione-2-monoxime (BDM), a myosin ATPase inhibitor
(29) that blocks muscle contractility by slowing the rate of
phosphate release from myosin after ATP hydrolysis (40) and
also inhibits the ATPase activity of both nonmuscle myosin II and
unconventional myosins (10). Treatment of CE cells
expressing ts LA29 v-Src with 10 mM BDM at the time of the
shift to the permissive temperature inhibited the translocation of
v-Src to focal adhesions (Fig. 4A, lower
right), although residual FAK-containing focal
adhesions persisted in treated cells (Fig. 4A, lower left). In
contrast, translocation of KD ts LA29 v-Src-KD to focal
adhesions was unaffected by BDM treatment (Fig. 4B, lower right).
Consistent with our previous findings, KD v-Src was localized in
enlarged focal adhesions that were stabilized as a consequence of
impaired turnover induced by the dominant-negative action of KD v-Src
(17). In addition to BDM, an inhibitor of MLCK, ML-7 (47), had similar effects on v-Src translocation (Fig. 4C).


View larger version (162K):
[in this window]
[in a new window]
|
FIG. 4.
The myosin ATPase inhibitor BDM and the MLCK inhibitor
ML7 block kinase-active v-Src translocation. CE cells expressing
ts LA29 v-Src (A) or KD ts LA29 v-Src-KD (B) were
maintained at 41°C or shifted to 35°C for 2 h in the presence
of BDM and stained with anti-Src (followed by a secondary antibody
coupled to FITC; right) and anti-FAK (followed by a secondary antibody
coupled to Texas red; left). Arrows, enlarged peripheral adhesions. (C)
Cells expressing ts LA29 v-Src (upper) or ts LA29
v-Src-KD (lower) after the shift to 35°C for 2 h in the absence
( ) or presence (+) of ML7 were stained with anti-Src (followed by a
secondary antibody coupled to FITC). Bars, 25 µm.
|
|
KD v-Src acts in a dominant-negative manner to inhibit actin
remodeling.
To investigate whether the different sensitivities to
BDM of kinase-active and KD v-Src were due to a difference in the
stability of cross-linked actin filaments, we examined the actin
cytoskeleton in v-Src-expressing, BDM-treated and untreated cells. At
the restrictive temperature, actin stress fibers could be visualized in
the absence of BDM (Fig. 5A, left) and
residual stress fibers were also still evident in kinase-active
v-Src-expressing cells after 2 h at the permissive temperature
(Fig. 5A, top right). However, we consistently observed that the
intensity of phalloidin-stained stress fibers was substantially greater
in the KD v-Src-expressing cells at the permissive temperature (Fig.
5A, bottom right). After treatment with BDM for 2 h, there were
few remaining stress fibers detected by phalloidin staining in cells
expressing either mutant of v-Src at the restrictive temperature,
although some cortical actin was still visible around the cell edges
(Fig. 5B, left). However, at the permissive temperature, there was a
substantial difference between kinase-active and KD v-Src-expressing
cells, with the latter displaying much higher levels of
phalloidin-staining actin even in the presence of BDM (Fig. 5B, right).
These data imply that BDM was inhibiting the new formation of
bundled actin filaments in cells in which the actin was being
dynamically regulated, i.e., in cells expressing either v-Src mutant at
the restrictive temperature or the kinase-active v-Src mutant at the
permissive temperature. However, in KD v-Src-expressing cells at the
permissive temperature, phalloidin-staining actin stress fibers were
unaffected by treatment with BDM, indicating that the existing actin
filaments were not being turned over and that cytoskeletal integrity
was independent of the new formation of bundled actin filaments.

View larger version (86K):
[in this window]
[in a new window]
|
FIG. 5.
Actin stress fiber stability is unaffected by BDM in
cells expressing KD ts LA29 v-Src at the permissive
temperature. CE cells expressing either ts LA29 v-Src or KD
ts LA29 v-Src-KD were maintained at 41°C or shifted to
35°C for 2 h and stained with phalloidin-FITC to visualize actin
stress fibers. Cells were either untreated ( BDM; A) or treated with
10 mM BDM for 2 h at 41°C or during the 2-h period of the shift
to 35°C (+ BDM; B).
|
|
Thus, the actin cytoskeleton was apparently stabilized as a consequence
of the dominant-negative effect of KD ts LA29 v-Src-KD at
the permissive temperature, and the requirement for myosin-dependent functions to maintain an organized cytoskeleton was lost. These findings imply that the role of myosin in the intracellular targeting of v-Src to focal adhesions is to maintain bundled actin stress fibers
in a state that is permissive for translocation when the actin is
constantly being remodeled. In contrast, when the actin cytoskeleton is
artificially stabilized by expression of KD v-Src, myosin ATPase
activity and the new formation of bundled actin stress fibers are no
longer required. Consistent with the observed cytoskeletal disassembly
in v-Src-transformed CE cells (16), these findings imply
that activated Src normally antagonizes the pathway leading to
myosin-induced cross-linking and organization of actin filaments during
routine remodeling of the actin cytoskeleton.
Stabilization of the adhesion and cytoskeletal network permits
translocation of KD v-Src into preexisting focal adhesions.
Since
one effect of KD ts LA29 v-Src was to inhibit the turnover
of bundled actin stress fibers and the adhesions at their termini, we
reasoned that translocation of this v-Src mutant must be in association
with existing stabilized actin and, therefore, into existing focal
adhesions. Thus, we examined merged images of BDM-treated CE cells
expressing KD v-Src which were double stained with anti-Src and
anti-FAK (Fig. 6A) or anti-Src and
antipaxillin (Fig. 6B). After 2 h at the permissive temperature,
intracellular complexes containing both v-Src and FAK were evident
(Fig. 6A, upper, yellow). At the cell periphery, v-Src-containing
complexes were evident in the most intracellular region of enlarged
focal adhesions (Fig. 6A, upper), which also contained FAK at the
membrane-proximal portion of the peripheral adhesions (Fig. 6A, upper,
red). Thus, KD v-Src that translocated to focal adhesions in the
presence of BDM was assembled into preexisting focal adhesions that
already contained FAK, as judged by the asymmetrical staining of the
enlarged adhesions with anti-FAK and anti-Src. In contrast, complete
colocalization of v-Src and FAK was evident in peripheral focal
adhesions of cells expressing kinase-active v-Src after 2 h at the
permissive temperature (visualized as yellow in Fig. 6A, lower),
indicating that v-Src and FAK were normally coassembled into new focal
adhesions when the actin-adhesion network was being dynamically
regulated.


View larger version (126K):
[in this window]
[in a new window]
|
FIG. 6.
KD v-Src can assemble into preexisting focal adhesions.
(A) Merged confocal images shown in Fig. 4B representing CE cells
expressing KD ts LA29 v-Src-KD (upper) that were shifted to
35°C for 2 h in the presence of BDM (+ BDM) and stained with
both anti-FAK (and a secondary antibody coupled to Texas red;
visualized as red) and anti-Src (and a secondary antibody coupled to
FITC; visualized as green). Grey arrow, intracellular complexes
containing both FAK and v-Src (visualized as yellow); broken white
arrows, enlarged peripheral adhesions containing FAK at the
membrane-proximal region (visualized as red); solid white arrows,
enlarged peripheral adhesions containing both FAK and v-Src at the
membrane-distal region (visualized as yellow). Also shown are merged
confocal images after dual staining of kinase-active ts LA29
v-Src-expressing cells (lower) that were shifted for 2 h to 35°C
with anti-FAK and anti-Src. Colocalization of v-Src and FAK is
visualized as yellow. (B) Merged confocal images after dual staining of
KD ts LA29 v-Src-KD-expressing cells (upper) or
kinase-active ts LA29 v-Src (lower) that were shifted for
2 h to 35°C with antipaxillin (and a secondary antibody coupled
to Texas red) and anti-Src (and a secondary antibody coupled to FITC).
Focal adhesions that stain with paxillin (visualized as red) in the
membrane-proximal region (broken arrows) and both Src and paxillin
(visualized as yellow) in the membrane-distal region (solid arrows) are
shown. Bars, 25 µm.
|
|
A similar asymmetrical staining pattern was evident with v-Src and
paxillin in KD v-Src-expressing cells at the permissive temperature. In
this case, v-Src-containing complexes were present at the intracellular
side of enlarged focal adhesions, with paxillin also present at the
membrane-proximal region (Fig. 6B, upper). In contrast, kinase-active
v-Src and paxillin completely colocalized in smaller focal adhesions at
the cell periphery (Fig. 6B, lower). These data indicate that, when the
actin cytoskeleton is artificially stabilized by the dominant-negative
action of KD v-Src, translocation into preexisting focal adhesions
occurs in association with stabilized stress fibers. Although the actin
stabilization that occurs in KD v-Src-expressing cells is artificially
induced, these findings are consistent with the notion that activated
Src normally translocates via preformed, myosin-induced bundled actin
stress fibers to focal adhesions forming at their termini.
FAK binds v-Src via the SH3 domain but is not a crucial Src
targeting partner.
Having established that the SH3 domain directs
the actomyosin-dependent targeting of v-Src to peripheral focal
adhesions, we sought to determine the nature of SH3-binding proteins
that mediate the translocation process. In our previous work, we
demonstrated that ts v-Src and FAK colocalized, both in
intracellular complexes containing focal adhesion proteins and in
mature focal adhesions at later times after a shift to the permissive
temperature (17). This, together with the fact that FAK
contains a well-defined focal adhesion targeting sequence
(30) and complexes with Src, at least in part, via
proline-rich sequences in FAK (50), made it a good candidate
for mediating the translocation of v-Src to focal adhesions.
Furthermore, FAK associates with v-Src mutants that are permissive for
translocation but defective for transformation (17). Thus,
we tested whether the SH3 mutant of v-Src, ts LA29 v-Src-W118A, which was unable to translocate, could associate with FAK.
Consistent with previous findings that mutation of a putative
SH3-binding proline-rich region of FAK suppressed binding to Src in
vivo (50), we found that FAK was not visibly
coimmunoprecipitated with the W118A mutant of v-Src that was defective
for translocation (Fig. 7A). This was in
contrast to results for mutants that were permissive
for translocation, including ts LA29 v-Src (Fig. 7A), its KD
derivative ts LA29 v-Src-KD (shown in reference
17), and a myristylation-defective ts
LA29 v-Src (shown in reference 17) which can
associate with FAK.


View larger version (69K):
[in this window]
[in a new window]
|
FIG. 7.
FAK binding v-Src via the Src SH3 domain is not required
for translocation. (A) v-Src was immunoprecipitated (IP) from lysates
of cells expressing ts LA29 v-Src or ts LA29
v-Src-W118A (-W118A) at 41°C and after a shift to 35°C for 2 h. Precipitated proteins were immunoblotted using both anti-FAK and
anti-Src as probes. The position of FAK coprecipitating with v-Src is
indicated. Immunoprecipitated v-Src is also indicated. The positions of
the 97- and 69-kDa molecular mass markers are shown. NI, nonimmune
serum. (B) Lysates of CE cells expressing ts LA29 v-Src
either alone ( ) or together with wild-type myc-tagged FAK
(wt) or a mutant in which Tyr-397 was replaced by Phe (397F) were
immunoblotted using anti-Src, anti-myc, or anti-FAK as the
probe. The exogenously expressed v-Src and FAK proteins are indicated.
Endogenous FAK is not visible on the exposure shown for the anti-FAK
blot, demonstrating the overexpression of exogenous retrovirus-encoded
FAK proteins (endogenous FAK is visible on longer exposures [not
shown]). (C) CE cells expressing both ts LA29 v-Src and
myc-tagged wild-type FAK or 397F-FAK were maintained at
41°C or were shifted to 35°C for 2 h. Lysates were
immunoprecipitated with anti-Src or anti-FAK and blotted using
anti-myc as the probe. The position of myc-tagged
FAK precipitated by anti-Src or anti-FAK is indicated. Anti-Src
immunoprecipitates were also probed with anti-FAK and anti-Src. (D) CE
cells expressing both ts LA29 v-Src and
myc-tagged FAK-397F were maintained at 41°C or were
shifted to 35°C for 2 h and were stained with anti-Src (followed
by a secondary antibody coupled to Texas red) and anti-myc
(followed by a secondary antibody coupled to FITC). Bars, 25 µm.
|
|
This correlation prompted us to further investigate whether FAK binding
was important for v-Src translocation. We expressed a variant of FAK
that is also unable to associate with v-Src as a result of mutation of
FAK Tyr-397, which binds the Src SH2 domain (397F-FAK). We confirmed
that both myc-tagged wild-type FAK and 397F-FAK were vastly
overexpressed relative to endogenous FAK (Fig. 7B, middle and lower).
Furthermore, although overexpressed wild-type FAK was
coimmunoprecipitated with anti-Src, we established that neither
exogenous 397F-FAK nor endogenous FAK was visibly complexed with v-Src
(Fig. 7C), confirming the findings of others (13, 50, 53)
and indicating that the overexpressed mutant FAK was acting as a
dominant-negative inhibitor of v-Src-FAK complex formation. However,
despite the inability of v-Src to bind FAK as a result of 397F-FAK
overexpression, ts v-Src translocated normally to focal
adhesions that also contained myc-tagged 397F-FAK after the
switch to the permissive temperature (Fig. 7D). These data suggest
that, although the association of v-Src and FAK required the Src SH3
domain, FAK was not the SH3-binding adapter protein that mediated actin
association and translocation of v-Src to focal adhesions. We confirmed
this interpretation by two other approaches. First, we overexpressed a
FAK mutant (FAK-Pro2) that has the proline-rich Src-binding sequences
mutated (50). We confirmed that this mutant suppressed
association between v-Src and FAK in ts v-Src-expressing CE
cells (Fig. 8A, immunoblot) but did not
inhibit the translocation of v-Src to focal adhesions (Fig. 8A).
Second, we expressed v-Src transiently in cells derived from
FAK
/
embryos (32) and could visualize v-Src
in peripheral focal adhesion structures (Fig. 8B).

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 8.
FAK is not essential for v-Src translocation. CE cells
expressing both ts LA29 v-Src and the FAK-Pro2 mutant were
maintained at 41°C or were shifted to 35°C for 2 h and stained
with anti-Src (followed by a secondary antibody coupled to Texas red)
and anti-myc (followed by a secondary antibody coupled to
FITC). To determine whether FAK was binding Src, lysates of cells
expressing wild-type (wt) FAK or FAK-Pro2 were immunoprecipitated (IP)
with anti-Src, blotted, and probed with anti-Myc (lower). The position
of FAK is indicated. (B) FAK / cells were transiently
transfected with the wild-type PrA strain of v-Src. Cells were fixed
and stained with anti-Src (followed by a secondary antibody coupled to
FITC). Arrows, focal adhesions containing v-Src. Also shown is an
immunoblot using anti-FAK as the probe confirming FAK deficiency in the
FAK / cells we used. Bars, 25 µm.
|
|
The p85 regulatory subunit of PI 3-kinase binds v-Src in an
SH3-dependent manner and is required for translocation.
Since the
association of FAK with v-Src was apparently not mediating focal
adhesion targeting, we tested the SH3 mutant v-Src protein, ts
LA29 v-Src-W118A, for binding to other potential regulators of Src
translocation. These included HSP90, the molecular chaperone that binds
to v-Src and that is essential for its function (5), p110AFAP, the actin filament-associated protein that acts
as a determinant of actin integrity (20, 45), and p85, the
regulatory subunit of PI 3-kinase that binds to v-Src and that is
implicated in signaling to the cytoskeleton (25, 31, 34, 49,
52). We found that while HSP90 and p110AFAP could be
coprecipitated with either ts LA29 v-Src or its SH3 mutant
derivative, ts LA29 v-Src-W118A (Fig.
9A), p85 could only be
coimmunoprecipitated with v-Src when the SH3 domain was functional (Fig. 9B, left). We previously showed that the association between ts LA29 v-Src and p85 was temperature dependent
(26), indicating that its binding to v-Src and also
activation of its associated lipid kinase activity only occurred after
a shift to the permissive temperature (26). In addition, we
and others, have shown using glutathione S-transferase-SH3
and -SH2 fusion proteins that p85 binds to the v-Src SH3 domain in
vitro (26, 39), although binding is modulated by the
adjacent SH2 domain (26). Here, using the discriminating SH3
domain mutant of v-Src, ts LA29 v-Src-W118A, we have
identified a requirement for the SH3 domain of v-Src for association
with cellular p85. In keeping with the requirement of SH3-dependent
association of v-Src with p85 for PI 3-kinase activation, we found that
the SH3 domain mutant of ts LA29 v-Src was unable to
stimulate Akt phosphorylation after a switch to the permissive
temperature, as judged by reactivity with an antibody recognizing Akt
Ser-473 in its phosphorylated form (2) (Fig. 9C). This was
in contrast to ts LA29 v-Src, which induced robust stimulation of Akt phosphorylation after a shift to the permissive temperature (Fig. 9C). Thus, the SH3 domain mutant of ts
v-Src that was unable to translocate to focal adhesions was also unable to associate with the regulatory subunit of PI 3-kinase or activate a
downstream signaling protein that is dependent on the lipid products of
PI 3-kinase. Our data clearly correlate the SH3 domain-PI 3-kinase
functional interaction with v-Src's focal adhesion targeting; however,
we previously found that although v-Src binds p85 via the SH3 domain,
the binding interaction is modulated by the adjacent Src SH2 domain
(26). This implies that the Src SH2 domain is also likely to
contribute to the SH3-dependent targeting of v-Src to focal adhesions.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 9.
The SH3 mutant v-Src protein binds HSP90 and
p110AFAP but not the p85 regulatory subunit of PI 3-kinase.
(A) Lysates of CE cells expressing ts LA29 v-Src or the SH3
mutant, ts LA29 v-Src-W118A, at 35°C were
immunoprecipitated (IP) with anti-Src and immunoblotted using
anti-HSP90, anti-p110AFAP, or anti-Src as the probe. The
positions of the individual immunoprecipitated proteins are shown. (B)
Lysates of CE cells expressing ts LA29 v-Src or the SH3
mutant, ts LA29 v-Src-W118A, at 35°C were
immunoprecipitated with anti-Src and immunoblotted using anti-p85 as
the probe (left). For comparison, the expression of both anti-p85
reactive forms was examined by immunoblotting whole-cell lysates using
anti-p85 as the probe (right). (C) Lysates of cells expressing ts
LA29 v-Src or the SH3 mutant, ts LA29 v-Src-W118A, that
were maintained at 41°C or shifted to 35°C for 30 or 60 min (in the
absence [ ] or presence [+] of LY294002) were immunoblotted using
anti-Akt-phospho-Ser-473 (upper) or anti-Akt (lower) as the probe. The
positions of phosphorylated Akt (phospho-Akt) and Akt are indicated.
|
|
The correlation between p85 binding and focal adhesion targeting
described above prompted us to test the effect of a selective inhibitor
of PI 3-kinase on the ability of ts v-Src to translocate to
focal adhesions after a shift to the permissive temperature. We found
that treatment of cells with LY294002 at a concentration that
effectively blocked the activation of Akt by v-Src (Fig. 9C),
suppressed the assembly of v-Src into focal adhesions (Fig. 10, right), although FAK persisted in
residual focal adhesions (Fig. 10A, left). In some cells, we observed
focal adhesion-like structures or complexes that remained in the
interior region of the cell (Fig. 10A, lower right). These findings
imply that the intracellular targeting of v-Src to focal adhesions
requires the activity of cellular PI 3-kinase, which we have shown to
bind to v-Src via the SH3 domain that is critical for the assembly of a
focal adhesion containing the oncoprotein. Furthermore, the specific
defect in cells treated with LY294002 might be in the peripheral
targeting of focal adhesion protein complexes once these have formed.

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 10.
The selective PI 3-kinase inhibitor LY294002 suppresses
targeting of v-Src to focal adhesions. (A) Cells expressing ts
LA29 v-Src at 30, 60, or 120 min after the switch to 35°C in the
presence of LY294002 were fixed and stained with anti-FAK (followed by
a secondary antibody coupled to Texas red) and anti-Src (followed by a
secondary antibody coupled to FITC). The retention of v-Src in the cell
interior is indicated (arrows). (B) Cells expressing ts LA29
v-Src either at 41°C or after 2 h at 35°C in the absence ( )
or presence (+) of LY294002 were fixed and stained with
phalloidin-FITC. Bars, 25 µm.
|
|
Since our previous work showed that the translocation of v-Src to
peripheral focal adhesions required actin stress fibers that were under
the control of RhoA (18), we examined the actin of cells
that had been treated with the selective PI 3-kinase inhibitor
LY294002. We found that the number of stress fibers in LY294002-treated
cells was considerably reduced, although peripheral actin was clearly
visible (Fig. 10B). Thus, the v-Src SH3-dependent association and
activation of PI 3-kinase most likely serve to maintain the integrity
of actin stress fibers that are required for the peripheral targeting
of v-Src.
 |
DISCUSSION |
Despite the long-standing evidence that v-Src was located in the
residual focal adhesions of transformed cells (37, 38, 41,
46), we still lack a detailed understanding of the mode of
intracellular targeting of this oncogenic tyrosine kinase and its
cellular counterparts. In addition to the assembly of the Src family
kinases into cell-ECM adhesions, the general mechanics of focal
adhesion assembly remain relatively obscure. Here we have used
conditionally translocated ts v-Src mutants to define critical regulatory features associated with the assembly of focal adhesions containing the oncoprotein. Although our work with the conditional v-Src mutants provides considerably greater detail on the
regulation of Src translocation, the analogy with previous reports on
the subcellular localization of c-Src (discussed below) implies that
these regulatory features are also relevant to the intracellular
targeting of the endogenous Src family kinases.
In its inactive state, v-Src colocalizes with regions of dense tubulin
staining in the perinuclear region and is diffusely located throughout
the cell after treatment with nocodazole (Fig. 3). After activation,
v-Src associates with polymerized actin in an SH3 domain-dependent
manner and is translocated to focal adhesions at stress fiber termini
(Fig. 3). These findings, together with our previous data
(17), indicate that v-Src switches from microtubule-dependent retention in the perinuclear region to associate with actin stress fibers. Furthermore, this switch is independent of
kinase activity and myristylation-mediated membrane association (17), although the latter is necessary for both perinuclear retention (17) and association with peripheral membranes.
These features of v-Src translocation are likely to be conserved also for c-Src, as suggested by immunofluorescence experiments that demonstrated a substantial proportion of exogenously expressed c-Src is
concentrated around the nucleus (35). Both exogenous and
endogenous c-Src colocalizes with microtubules as well as markers of
endosomes and the trans-Golgi and is present at the microtubule
organizing center, an area of the cell that is rich in membranous
organelles (35). Furthermore, when Tyr-527 of c-Src is not
phosphorylated, so that Src is in the open and active conformation,
c-Src is translocated to focal adhesions by a mechanism that requires
only the amino-terminal portion of c-Src containing the homology
domains (36). Thus, activation of the Src protein is
accompanied by a switch between subcellular cytoskeletal networks, a
switch that is an integral feature of its intracellular targeting.
Our previous work had also established that RhoA-mediated actin
organization was essential for translocation of v-Src to focal adhesions (18). RhoA is known to induce MLC phosphorylation via Rho kinase or MLCK and, consequently, to stimulate myosin ATPase
activity and actin filament cross-linking into stress fibers that are
under high tension (48). We found that the RhoA requirement of v-Src translocation was reflected also in a requirement for myosin
activity and the integrity of tensile actin stress fibers. Consistent
with this, MLC was visibly associated with stress fibers in CE cells
used in these studies (Fig. 3), and the myosin ATPase inhibitor BDM or
the MLCK inhibitor ML7 blocked the translocation of kinase-active v-Src
(Fig. 4). However, the translocation of kinase-defective v-Src and the
integrity of phalloidin-staining stress fibers in cells expressing this
mutant protein at the permissive temperature were insensitive to myosin
inhibitors (Fig. 4 and 5). These findings indicate that the
dominant-negative action of KD v-Src traps the actin cytoskeleton in a
stable state that is permissive for translocation, without new assembly
of cross-linked actin filaments. These data also imply that the primary
role of myosin in v-Src translocation is to maintain the integrity of cellular actin stress fibers.
The finding that KD ts v-Src induces actin stability (Fig.
5) and the formation of enlarged focal adhesions (Fig. 4 and 6) (17) implies that focal adhesion size is determined by
turnover that normally occurs during the routine assembly-disassembly
cycle of the adhesion-cytoskeletal network. Furthermore, enlarged
adhesions arise from continued assembly of focal adhesion protein
complexes into preexisting adhesions that are not turning over and that are associated with stabilized actin. Consequently, cells that have
enlarged stabilized focal adhesions are overadhered and exhibit impaired cell motility (17). These results further imply
that, under these conditions, some focal adhesion components form a complex in the interior part of the cell and can be translocated to
existing adhesions at the ends of stable actin stress fibers (Fig. 6).
Together with the lack of a requirement for further myosin ATPase
function under these conditions, this suggests that it is primarily the
integrity of the actin stress fibers tethered into stabilized adhesions
that directs the targeting of the focal adhesion protein complexes
containing v-Src to these sites.
In keeping with the model for focal adhesion assembly proposed by
Burridge and Chrzanowska-Wodnicka, i.e., that integrin clustering during adhesion formation is driven by intracellular activities, including RhoA- and myosin-induced contractility (6, 9), our
data imply that intracellular stimuli that trigger the translocation of
signaling proteins from the cell interior to focal adhesions also rely
on the cytoskeletal organization induced by RhoA and myosin.
Interestingly, one further interpretation of our results is that
activated Src antagonizes the RhoA/myosin pathway, thus contributing to disassembly of contractile stress fibers during normal cytoskeletal remodeling or oncogenic transformation, and that
the KD v-Src interferes with this process. In this way, the dominant-negative v-Src mutant alters the balance in favor of maintenance of contractile actin stress fibers. One potential candidate
for Src-induced antagonism of the RhoA/myosin pathway is
p190RhoGAP, which is tyrosine phosphorylated and
enzymatically activated in response to v-Src (14, 16).
Although the SH3 domain of v-Src is required for the association of FAK
and although FAK contains a known focal adhesion targeting sequence,
overexpression of mutant FAK proteins that inhibit the binding of v-Src
to FAK does not interfere with translocation (Fig. 7 and 8). In
addition, v-Src can localize in the focal adhesions of
FAK
/
cells (Fig. 8), indicating that FAK binding is not
critical for v-Src translocation. By an investigation of other
potential Src-binding proteins that are known to influence Src
functionality or actin integrity, we found that HSP90 and
p110AFAP could bind to the SH3 mutant v-Src protein (Fig.
9). However, the association with the p85 regulatory subunit of PI
3-kinase and v-Src-induced Akt phosphorylation that is downstream of PI 3-kinase were SH3 dependent (Fig. 9), correlating with the SH3 dependence of v-Src's peripheral targeting. To distinguish between cause and effect, we used LY294002, the selective PI 3-kinase inhibitor, to demonstrate that the translocation of v-Src to peripheral focal adhesions required the activity of PI 3-kinase (Fig. 10). Furthermore, we demonstrated that treatment with LY294002 substantially reduced the number of actin stress fibers in treated cells (Fig. 10),
indicating that the role of the v-Src SH3-dependent association and
activation of PI 3-kinase is most likely to maintain actin stress
fibers. The important role that we have identified for the Src SH3
domain and for its binding partner p85 might reflect a more general
role for SH3 domains and PI 3-kinase in cytoskeleton-mediated peripheral targeting of other cellular proteins that contain SH3 domains and that associate with actin.
In conclusion, inactive Src is retained in the interior of the cell,
most likely via myristylation-dependent endosomal membrane association
and the microtubule network. Upon conformational activation, Src
associates with polymerized actin and is assembled into focal adhesions
at actin stress fiber termini in an SH3- and PI 3-kinase-dependent manner. Use of a KD, a dominant-negative mutant of Src that induces artificial stabilization of the adhesion-cytoskeletal network allowed
us to deduce that myosin ATPase also plays an important role by
maintaining actin filaments in a state that is permissive for Src
translocation. Under these conditions, focal adhesion protein complexes
that include v-Src assemble into preexisting focal adhesions. Thus, the
intracellular targeting and catalytic activity of ts v-Src,
and most likely also c-Src, are tightly and coordinately regulated by
simultaneous release of constraints on the SH3 domain and kinase
activity. By this means, inadvertent adhesion disruption as a result of
inappropriate localization of kinase-active Src to focal adhesions is avoided.
 |
ACKNOWLEDGMENTS |
We thank John Wyke, Fedor Berditchevski, and Steve Winder for
their comments on the manuscript and Tom Parsons for RCAS-FAK, Mike
Schaller for the FAK-Pro2 mutant, Dusko Ilic for the
FAK
/
cells, and Dan Flynn for antibodies to
p110AFAP.
This work was funded by the Cancer Research Campaign (United Kingdom).
V.B. was supported by an MRC project grant.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: The Beatson
Institute for Cancer Research, CRC Beatson Laboratories, Garscube
Estate, Switchback Rd., Bearsden, Glasgow G61 1BD, United Kingdom.
Phone: 0141-330-3953. Fax: 0141-942-6521. E-mail:
m.frame{at}beatson.gla.ac.uk.
 |
REFERENCES |
| 1.
|
Adelstein, R. S.
1983.
Regulation of contractile proteins by phosphorylation.
J. Clin. Investig.
72:1863-1866.
|
| 2.
|
Alessi, D. R.,
M. Andjelkovic,
B. Caudwell,
P. Cron,
N. Morrice,
P. Cohen, and B. A. Hemmings.
1996.
Mechanism of activation of protein kinase B by insulin and IGF-1.
EMBO J.
15:6541-6551[Medline].
|
| 3.
|
Aplin, A. E.,
A. Howe,
S. K. Alahari, and R. L. Juliano.
1998.
Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins.
Pharmacol. Rev.
50:197-263[Abstract/Free Full Text].
|
| 4.
|
Beug, H.,
M. Claviez,
B. M. Jockusch, and T. Graf.
1978.
Differential expression of Rous sarcoma virus-specific transformation parameters in enucleated cells.
Cell
14:843-856[CrossRef][Medline].
|
| 5.
|
Brugge, J. S.
1986.
Interaction of the Rous sarcoma virus protein pp60src with the cellular proteins pp50 and pp90.
Curr. Top. Microbiol. Immunol.
123:1-22[Medline].
|
| 6.
|
Burridge, K., and M. Chrzanowska-Wodnicka.
1996.
Focal adhesions, contractility, and signaling.
Annu. Rev. Cell Dev. Biol.
12:463-518[CrossRef][Medline].
|
| 7.
|
Burridge, K.,
K. Fath,
T. Kelly,
G. Nuckolls, and C. Turner.
1988.
Focal adhesions: transmembrane junctions between the extracellular matrix and the cytoskeleton.
Annu. Rev. Cell Biol.
4:487-525[CrossRef].
|
| 8.
|
Calalb, M. B.,
T. R. Polte, and S. K. Hanks.
1995.
Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases.
Mol. Cell. Biol.
15:954-963[Abstract].
|
| 9.
|
Chrzanowska-Wodnicka, M., and K. Burridge.
1996.
Rho-stimulated contractility drives the formation of stress fibers and focal adhesions.
J. Cell Biol.
133:1403-1415[Abstract/Free Full Text].
|
| 10.
|
Cramer, L. P., and T. J. Mitchison.
1995.
Myosin is involved in postmitotic cell spreading.
J. Cell Biol.
131:179-189[Abstract/Free Full Text].
|
| 11.
|
DeClue, J. E., and G. S. Martin.
1989.
Linker insertion-deletion mutagenesis of the v-src gene: isolation of host- and temperature-dependent mutants.
J. Virol.
63:542-554[Abstract/Free Full Text].
|
| 12.
|
de Lanerolle, P., and R. J. Paul.
1991.
Myosin phosphorylation/dephosphorylation and regulation of airway smooth muscle contractility.
Am. J. Physiol.
261:L1-L14[Abstract/Free Full Text].
|
| 13.
|
Eide, B. L.,
C. W. Turck, and J. A. Escobedo.
1995.
Identification of Tyr-397 as the primary site of tyrosine phosphorylation and pp60src association in the focal adhesion kinase pp125FAK.
Mol. Cell. Biol.
15:2819-2827[Abstract].
|
| 14.
|
Ellis, C.,
M. Moran,
F. McCormick, and T. Pawson.
1990.
Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases.
Nature
343:377-381[CrossRef][Medline].
|
| 15.
|
Erpel, T.,
G. Superti-Furga, and S. A. Courtneidge.
1995.
Mutational analysis of the Src SH3 domain: the same residues of the ligand binding surface are important for intra- and intermolecular interactions.
EMBO J.
14:963-975[Medline].
|
| 16.
|
Fincham, V. J.,
A. Chudleigh, and M. C. Frame.
1999.
Regulation of p190 Rho-GAP by v-Src is linked to cytoskeletal disruption during transformation.
J. Cell Sci.
112:947-956[Abstract].
|
| 17.
|
Fincham, V. J., and M. C. Frame.
1998.
The catalytic activity of Src is dispensable for translocation to focal adhesions but controls the turnover of these structures during cell motility.
EMBO J.
17:81-92[CrossRef][Medline].
|
| 18.
|
Fincham, V. J.,
M. Unlu,
V. G. Brunton,
J. D. Pitts,
J. A. Wyke, and M. C. Frame.
1996.
Translocation of Src kinase to the cell periphery is mediated by the actin cytoskeleton under the control of the Rho family of small G proteins.
J. Cell Biol.
135:1551-1564[Abstract/Free Full Text].
|
| 19.
|
Fincham, V. J.,
J. A. Wyke, and M. C. Frame.
1995.
v-Src-induced degradation of focal adhesion kinase during morphological transformation of chicken embryo fibroblasts.
Oncogene
10:2247-52[Medline]. (Erratum, 11:2185.)
|
| 20.
|
Flynn, D. C.,
T. H. Leu,
A. B. Reynolds, and J. T. Parsons.
1993.
Identification and sequence analysis of cDNAs encoding a 110-kilodalton actin filament-associated pp60src substrate.
Mol. Cell. Biol.
13:7892-7900[Abstract/Free Full Text].
|
| 21.
|
Frame, M. C.,
K. Simpson,
V. J. Fincham, and D. H. Crouch.
1994.
Separation of v-Src-induced mitogenesis and morphological transformation by inhibition of AP-1.
Mol. Biol. Cell
5:1177-1184[Abstract].
|
| 22.
|
Fuerstenberg, S.,
H. Beug,
M. Introna,
K. Khazaie,
A. Mu noz,
S. Ness,
K. Nordström,
J. Sap,
I. Stanley,
M. Zenke, and B. Vennström.
1990.
Ectopic expression of the erythrocyte band 3 anion exchange protein, using a new avian retrovirus vector.
J. Virol.
64:5891-902[Abstract/Free Full Text].
|
| 23.
|
Gilmore, A. P., and L. H. Romer.
1996.
Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation.
Mol. Biol. Cell
7:1209-1224[Abstract].
|
| 24.
|
Guan, J. L., and D. Shalloway.
1992.
Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation.
Nature
358:690-692[CrossRef][Medline].
|
| 25.
|
Guinebault, C.,
B. Payrastre,
C. Racaud-Sultan,
H. Mazarguil,
M. Breton,
G. Mauco,
M. Plantavid, and H. Chap.
1995.
Integrin-dependent translocation of phosphoinositide 3-kinase to the cytoskeleton of thrombin-activated platelets involves specific interactions of p85 alpha with actin filaments and focal adhesion kinase.
J. Cell Biol.
129:831-842[Abstract/Free Full Text].
|
| 26.
|
Haefner, B.,
R. Baxter,
V. J. Fincham,
C. P. Downes, and M. C. Frame.
1995.
Cooperation of Src homology domains in the regulated binding of phosphatidylinositol 3-kinase. A role for the Src homology 2 domain.
J. Biol. Chem.
270:7937-7943[Abstract/Free Full Text].
|
| 27.
|
Hall, A.
1998.
Rho GTPases and the actin cytoskeleton.
Science
279:509-514[Abstract/Free Full Text].
|
| 28.
|
Hanks, S. K.,
M. B. Calalb,
M. C. Harper, and S. K. Patel.
1992.
Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin.
Proc. Natl. Acad. Sci. USA
89:8487-8491[Abstract/Free Full Text].
|
| 29.
|
Higuchi, H., and S. Takemori.
1989.
Butanedione monoxime suppresses contraction and ATPase activity of rabbit skeletal muscle.
J. Biochem. (Tokyo)
105:638-643[Abstract/Free Full Text].
|
| 30.
|
Hildebrand, J. D.,
M. D. Schaller, and J. T. Parsons.
1993.
Identification of sequences required for the efficient localization of the focal adhesion kinase, pp125FAK, to cellular focal adhesions.
J. Cell Biol.
123:993-1005[Abstract/Free Full Text].
|
| 31.
|
Hill, K.,
S. Welti,
J. Yu,
J. T. Murray,
S. C. Yip,
J. S. Condeelis,
J. E. Segall, and J. M. Backer.
2000.
Specific requirement for the p85-p110alpha phosphatidylinositol 3-kinase during epidermal growth factor-stimulated actin nucleation in breast cancer cells.
J. Biol. Chem.
275:3741-3744[Abstract/Free Full Text].
|
| 32.
|
Ilic, D.,
E. A. Almeida,
D. D. Schlaepfer,
P. Dazin,
S. Aizawa, and C. H. Damsky.
1998.
Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis.
J. Cell Biol.
143:547-560[Abstract/Free Full Text].
|
| 33.
|
Jockusch, B. M.,
P. Bubeck,
K. Giehl,
M. Kroemker,
J. Moschner,
M. Rothkegel,
M. Rudiger,
K. Schluter,
G. Stanke, and J. Winkler.
1995.
The molecular architecture of focal adhesions.
Annu. Rev. Cell Dev. Biol.
11:379-416[CrossRef] |